Bharat Parenterals Ltd
BSE:541096
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its Industry Average (29.2), the stock would be worth ₹-1 153.32 (196% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -30.5 | ₹1 205.5 |
0%
|
| Industry Average | 29.2 | ₹-1 153.32 |
-196%
|
| Country Average | 23 | ₹-907.84 |
-175%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
B
|
Bharat Parenterals Ltd
BSE:541096
|
8.3B INR | -30.5 | -102.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
825.8B USD | 48 | 39.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
548.5B USD | 22.4 | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.6B GBP | 19.3 | 27.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
220.1B CHF | 14.2 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.3B USD | 16.6 | 15 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 907.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 9.5 | 11.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
150.6B USD | 12.8 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.3B USD | 8.3 | 16.6 |
Market Distribution
| Min | 0.5 |
| 30th Percentile | 14 |
| Median | 23 |
| 70th Percentile | 39.7 |
| Max | 28 676 |
Other Multiples
Bharat Parenterals Ltd
Glance View
Bharat Parenterals Ltd. engages in the manufacture of pharmaceutical formulations. The company is headquartered in Vadodara, Gujarat. The company went IPO on 2018-03-21. The firm is engaged in research, development, manufacturing, marketing, sourcing and distribution of pharmaceutical products. The firm offers a range of products, including B-lactam antibiotics, anti-retroviral, cephalosporins antibiotics, antiprotozoal / anthelmintic, respiratory, antiallergic / anti histaminic / anticold, cleansing agents/skin infections, antibiotic, cardiovascular system, anti-diabetic, anti-tuberculosis, anti-fungal, antimalarial, gastroinestinaltract / alimentary system, anti-inflammatory / anti pyretic / analgesic, supplements, central nervous system, anesthetics, anti-viral, steroids and hormones, uterine stimulant, anticancer and other.
